Prime Medicine, Inc. (PRME)
NASDAQ: PRME · Real-Time Price · USD
1.889
-0.101 (-5.06%)
Mar 31, 2025, 1:25 PM EDT - Market open
Prime Medicine Stock Forecast
PRME's stock price has decreased by -73.39% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Prime Medicine stock have an average target of 13.25, with a low estimate of 10 and a high estimate of 18. The average target predicts an increase of 601.32% from the current stock price of 1.89.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Prime Medicine stock from 9 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 6 | 6 |
| Buy | 2 | 2 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 9 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $15 → $16 | Strong Buy | Maintains | $15 → $16 | +746.87% | Mar 20, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +429.30% | Mar 19, 2025 |
| Citizens Capital Markets | Citizens Capital Markets | Buy Reiterates $10 | Buy | Reiterates | $10 | +429.30% | Mar 4, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +429.30% | Mar 3, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $15 | Strong Buy | Maintains | $15 | +693.94% | Mar 3, 2025 |
Financial Forecast
Revenue This Year
6.76M
from 2.98M
Increased by 126.72%
Revenue Next Year
35.32M
from 6.76M
Increased by 422.22%
EPS This Year
-1.24
from -1.65
EPS Next Year
-1.20
from -1.24
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 26.3M | 194.3M | 141.8M | ||
| Avg | 6.8M | 35.3M | 33.5M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 780.0% | 2,772.2% | 301.4% | ||
| Avg | 126.7% | 422.2% | -5.1% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.81 | -0.64 | -0.60 | ||
| Avg | -1.24 | -1.20 | -1.16 | ||
| Low | -1.42 | -1.47 | -1.62 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.